This Fund Leaned Into 2025's Big Biotech Rally with a $9.5 Million Bet on Mineralys

3 days ago 7

Jonathan Ponciano, The Motley Fool

Thu, November 27, 2025 astatine 10:34 AM CST 4 min read

New York City-based Findell Capital Management added 250,000 shares of MLYS, valued astatine $9.5 million, successful the 3rd quarter.
The acquisition marked a caller presumption for Findell, which reported holding nary shares of MLYS successful the erstwhile quarter.
MLYS inactive places extracurricular the fund's apical 5 holdings.
These 10 stocks could mint the adjacent question of millionaires ›

New York City-based Findell Capital Management disclosed a caller $9.5 cardinal presumption successful Mineralys Therapeutics (NASDAQ:MLYS) arsenic of its November 14 SEC filing.

According to a filing with the Securities and Exchange Commission dated November 14, Findell Capital Management initiated a caller presumption successful Mineralys Therapeutics (NASDAQ:MLYS), acquiring 250,000 shares successful the 3rd quarter. The involvement was valued astatine $9.5 million, representing 3.7% of the fund’s $253.4 cardinal U.S. equity portfolio arsenic of September 30. The money reported 15 positions successful total.

Top holdings aft the filing:

NASDAQ:LQDA: $64.4 cardinal (29.4% of AUM)
NASDAQ:ESTA: $53.1 cardinal (24.2% of AUM)
NASDAQ:OPRT: $15.8 cardinal (7.2% of AUM)
NASDAQ:ODP: $14.9 cardinal (6.8% of AUM)
NYSE:GEO: $11.5 cardinal (5.2% of AUM)

As of Wednesday's marketplace close, shares of Mineralys Therapeutics were priced astatine $43.36, up a staggering 246% implicit the past twelvemonth and acold outperforming the S&P 500's 13% summation successful the aforesaid period.

Metric

Value

Market Capitalization	$3.4 billion
Net Income (TTM)	($171.4 million)
Price (as of marketplace adjacent Wednesday)	$43.36

Mineralys Therapeutics is simply a clinical-stage biotechnology institution focused connected advancing therapies for hypertension and cardiovascular diseases. The institution leverages its proprietary candidate, lorundrostat, to code important unmet needs successful resistant hypertension. Lorundrostat is an orally administered aldosterone synthase inhibitor targeting uncontrolled oregon resistant hypertension. Primary customers are expected to beryllium healthcare providers and patients suffering from hypertension and related cardiovascular conditions.

Investors mightiness privation to instrumentality enactment erstwhile a manager allocates meaningful superior to a pre-revenue biotech with a rapidly shifting hazard profile. Findell’s caller involvement successful Mineralys reflects a stake connected a institution whose valuation has been driven astir wholly by objective advancement and superior markets momentum. Shares person surged since the institution upsized its $250 cardinal offering announced connected September 2—an lawsuit that materially expanded its currency runway and signaled rising organization support. The institution yet raised $287.5 cardinal done the offering. For semipermanent investors, that backdrop whitethorn substance arsenic overmuch arsenic the subject itself.

Mineralys ended the 3rd 4th with nary merchandise gross and a nett nonaccomplishment of $36.9 cardinal successful the period, but it reported continued advancement of lorundrostat, its aldosterone synthase inhibitor being developed for resistant hypertension. The institution is inactive aboriginal successful its lifecycle, utilizing superior chiefly for R&D, manufacturing, and pre-commercial planning. That profile—high risk, but with a perchance ample addressable market—isn't antithetic crossed Findell’s portfolio, which includes concentrated aesculapian bets specified arsenic Liquidia.